Profile data is unavailable for this security.
About the company
Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.
- Revenue in HKD (TTM)1.62bn
- Net income in HKD262.89m
- Incorporated2000
- Employees1.46k
- LocationEssex Bio-Technology LtdRoom 2818,Chn Mrchnts Twr,Shn Tk Ctr168-200 Connaught Road CentralCentral Hong KongHKG
- Phone+852 25877838
- Fax+852 25877363
- Websitehttp://www.essexbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pak Fah Yeow International Ltd | 265.21m | 96.45m | 760.40m | 101.00 | 7.89 | 1.01 | 7.33 | 2.87 | 0.3094 | 0.3094 | 0.8507 | 2.41 | 0.2869 | 2.84 | 23.53 | 2,600,118.00 | 10.44 | 3.99 | 11.32 | 4.18 | 87.05 | 80.79 | 36.37 | 21.27 | 4.22 | 5.26 | 0.0055 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
| Zhongzhi Pharmaceutical Holdings Ltd | 2.20bn | 119.57m | 777.24m | 2.74k | 6.37 | 0.6538 | 3.36 | 0.354 | 0.1412 | 0.1412 | 2.59 | 1.38 | 1.09 | 2.68 | 7.39 | 830,705.70 | 5.99 | 7.69 | 9.17 | 11.75 | 57.55 | 60.44 | 5.49 | 6.73 | 0.9033 | 213.59 | 0.1516 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | -- |
| Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 901.25m | 184.38m | 789.95m | 678.00 | 4.28 | 0.4641 | 6.38 | 0.8765 | 0.3291 | 0.3291 | 1.61 | 3.04 | 0.3574 | 2.10 | 2.94 | 1,062,796.00 | 7.31 | 7.67 | 10.25 | 10.48 | 75.46 | 78.79 | 20.46 | 20.68 | 1.62 | -- | 0.0502 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
| Hbm Holdings Ltd | 562.02m | 165.78m | 979.73m | 158.00 | 5.68 | 0.9833 | 5.00 | 1.74 | 0.2253 | 0.2253 | 0.7623 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,175,272.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
| Jbm (Healthcare) Ltd | 648.42m | 130.46m | 1.16bn | 279.00 | 9.53 | 1.21 | 6.31 | 1.79 | 0.1479 | 0.1479 | 0.7338 | 1.17 | 0.4645 | 4.25 | 5.98 | 2,324,068.00 | 9.83 | 4.38 | 12.04 | 5.52 | 52.14 | 46.47 | 21.16 | 12.69 | 1.25 | 89.68 | 0.1155 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| SinoMab Bioscience Ltd | 2.18m | -214.45m | 1.28bn | 214.00 | -- | 4.29 | -- | 586.93 | -0.2059 | -0.2059 | 0.0021 | 0.2725 | 0.0023 | -- | -- | 10,122.40 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.51bn | 1.46k | 5.93 | 0.7519 | 4.77 | 0.9358 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.60bn | 1.72k | 7.31 | 0.6678 | 4.55 | 1.09 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| Cryofocus Medtech Shanghai Co Ltd | 44.59m | -114.14m | 1.67bn | 370.00 | -- | 13.17 | -- | 37.38 | -0.4774 | -0.4774 | 0.1865 | 0.5293 | 0.1881 | 0.418 | 4,369.58 | 113,752.20 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| Ascletis Pharma Inc | 10.84m | -277.65m | 1.80bn | 219.00 | -- | 0.7957 | -- | 165.88 | -0.2674 | -0.2674 | 0.0104 | 2.31 | 0.0041 | 1.34 | 3.58 | 49,491.39 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.16bn | 604.88m | 1.85bn | 1.18k | 3.05 | 0.5257 | 2.70 | 1.59 | 0.4027 | 0.4027 | 0.7714 | 2.34 | 0.2838 | 2.05 | 6.17 | 1,013,738.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| VIVA Biotech Holdings | 2.14bn | -341.59k | 1.90bn | 2.04k | -- | 0.4684 | 7.61 | 0.888 | -0.0054 | -0.0054 | 1.04 | 1.90 | 0.2603 | 5.26 | 5.18 | 1,031,897.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
Data as of Nov 22 2024. Currency figures normalised to Essex Bio-Technology Ltd's reporting currency: Hong Kong Dollar HKD
3.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Aug 2024 | 12.58m | 2.22% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 4.51m | 0.79% |
| Pheim Asset Management Sdn. Bhd.as of 30 Jun 2024 | 3.63m | 0.64% |
| CATAM Asset Management AGas of 31 Mar 2021 | 300.00k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 182.72k | 0.03% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 141.00k | 0.03% |
| Strategic Advisers LLCas of 30 Sep 2024 | 91.00k | 0.02% |
| DFA Australia Ltd.as of 30 Sep 2024 | 76.83k | 0.01% |
| AXA Investment Managers UK Ltd.as of 30 Sep 2024 | 68.00k | 0.01% |
| EntrepreneurShares LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
